MarginsXMarginsX
Home › Markets › Health Care › FENC

Fennec Pharmaceuticals Inc. (FENC)

FENC trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$12.76
+9.81% on the day
Market cap
$450.5M
Small cap
Revenue · 2025
$44.6M
-6.1% on 2024
Net income · 2025
-$9.7M
-21.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/0001104659-26-036182-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerFENC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001211583
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inBC
Canadian listingTSX: FRX

Financials · 2025

LineValue
Revenue$44.6M
Net income-$9.7M
Operating income-$6.3M
Net margin-21.8%
Operating margin-14.1%
Revenue growth-6.1%
Cash$36.8M
Total assets$70.6M
P/E (computed)Net income was not positive
P/S (computed)10.1×

Warning signs

Cash runway
Cash-flow positive
$48.7M cash at September 30, 2026
Share count, 1 year
+25.6%
2025-11-10 to 2026-11-10 · +32.6% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$12.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$48.7M cash; operating cash flow $787K a quarter.Report 2026-09-30
Shares outstanding35,305,117 (2026-11-10); 28,116,829 a year earlier; 26,634,676 three years earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2025-11-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorHaskell & White LLP, Irvine, California, United StatesPCAOB Form AP 2026-05-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $12.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$19.6M$4.6M$6.7M$48.7MNo debt tags$66.4M10-Q 2026-11-12
Q2 2026
2026-06-30
$17.9M$2.0M$50K$41.2MNo debt tags$59.2M10-Q 2026-08-13
Q1 2026
2026-03-31
$15.1M$201K$2.4M$40.2MNo debt tags$51.0M10-Q 2026-05-14
Q4 2025
2025-12-31
$13.8M-$4.8M-$6.0M$36.8MNo debt tags$44.6M10-K 2026-03-27
Q3 2025
2025-09-30
$12.5M-$638K$1.5M$21.9M$19.4M$38.8M10-Q 2026-11-12
Q2 2025
2025-06-30
$9.7M-$3.2M-$3.7M$18.7M$19.4M$33.3M10-Q 2026-08-13
Q1 2025
2025-03-31
$8.8M-$1.2M-$4.3M$22.7M$19.4M$30.9M10-Q 2026-05-14
Q4 2024
2024-12-31
$7.9M-$2.0M-$1.5M$26.6M$19.3M$47.5M10-K 2026-03-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-11-18
Latest annual report10-K2026-03-27
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-09-17
Latest proxyDEF 14A2026-04-28

Source: SEC EDGAR submissions feed, 858 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+18.5%
1 month+14.1%
3 months-3.6%
Year to date+50.9%
1 year+51.1%
From 52-week high-9.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CADLCandel Therapeutics Inc.$5.81-6.29%$455.8M
TVGNTevogen Inc.$6.22+3.67%$422.2M
RGNXREGENXBIO Inc.$7.32-4.19%$484.0M
TECXTectonic Therapeutic Inc.$20.98-0.76%$418.5M
IRLAIRulya Therapeutics Inc.$37.36-6.13%$405.0M
SLBTSL Science Holding Limited$0.7195-3.42%$403.5M
ETRAElectra Therapeutics Inc.$8.31-6.00%$522.4M
ENTXEntera Bio Ltd.$3.02-2.89%$525.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier